证券代码：600299 证券简称：安迪苏 公告编号：2023-026 蓝星安迪苏股份有限公司 2023 年三季度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 蓝星安迪苏股份有限公司（以下简称"安迪苏"或"公司"）根据上海证券交 易所发布的《上市公司行业信息披露指引第十三号——化工》（2022年修订）和 《关于做好上市公司 2023 年第三季度报告披露工作的通知》的要求，现将公司 2023 年前三季度主要经营数据披露如下： 一、 主要产品销售情况 营业收入分产品情况 单位:元 币种:人民币 | | | | 主营业务分产品情况 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 分产品 | 营业收入 | 营业成本(注) | 毛利率 | 营业收 入比上 | 营业成本 比上年增 | | 毛利率比上年增 | | | | | | 年增减 | 减 | | 减（%） | | 功能性产品 | 6,395,876,706 | 5,776,445,667 | ...

根据中国证券监督管理委员会《上市公司独立董事管理办法》《上市公司 治理准则》《上海证券交易所股票上市规则》（以下简称"《股票上市规 则》"）及《蓝星安迪苏股份有限公司章程》（以下简称"《公司章程》"）与 蓝星安迪苏股份有限公司（以下简称"公司"）《独立董事工作制度》的有关规 定，作为公司独立董事，本着实事求是、认真负责的态度，基于独立判断的立 场，对公司第八届董事会第十三次会议审议的议案，发表独立意见如下： 蓝星安迪苏股份有限公司 独立董事关于第八届董事会第十三次会议相关议案的 独立意见 我们认为，公司提名孙岩峰先生为董事候选人事项符合相关法律、法规、 规范性文件及《公司章程》的有关规定，提名程序和表决程序合法合规，不 存在损害股东合法利益，尤其是中小股东合法利益的情形。公司董事候选人 孙岩峰先生不存在《公司法》《公司章程》以及中国证监会、上海证券交易 所有关规定中不得担任公司董事的情形。因此，我们同意提名孙岩峰先生为 公司董事候选人，并同意将该事项提交公司股东大会审议。 2. 关于《聘任蔡昀女士为公司董事会秘书》的议案 我们认为，经审核董事会秘书候选人的个人履历及资料，蔡昀女士已取 得董事会秘书资格证书，其 ...

三、接待人员 蓝星安迪苏股份有限公司 蓝星安迪苏股份有限公司 2023 年半年度业绩说明会沟通记录 一、会议时间： 2023 年 9 月 28 日 （星期四）16:00-17:00 二、参会人员或机构 董事长兼总经理（CEO）：郝志刚先生 独立董事：臧恒昌先生 副总经理兼首席运营官：Frederic Jacquin 先生 首席财务官：Virginie Cayatte 女士 传播及数字化总监：蔡昀女士 董事会秘书：梁齐南女士 四、会议地点 通过上证路演中心线上提问的投资者 3. 公司近期公告的 3.7 万吨多特种添加剂项目，需要多少投资金额？估计合适 完工能投产？ 公司通过上证路演中心平台就投资者普遍关注的问题进行回答。沟通内容 如下： 感谢您对我们公司近期的 3.7 万吨多特种添加剂项目的关注。安迪苏正 积极践行全球"双支柱"战略，在巩固蛋氨酸行业领导地位的同时，加速 发展特种产品业务。FOSIC 项目是安迪苏"双支柱"战略的重要组成部分 之一，也是安迪苏"中国一体化战略"持续推进的标志事件之一。关于投 资金额和完工投产时间，由于涉及商业机密和具体情况，我们会按照计划 和时间表，努力推进项目的进展，并在符合披 ...

证券代码：600299 证券简称：安迪苏 公告编号：2023-023 蓝星安迪苏股份有限公司 重要内容提示： 蓝星安迪苏股份有限公司（以下简称"公司"）已于 2023 年 8 月 5 日披露公 司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年度 经营成果、财务状况，公司计划于 2023 年 09 月 28 日下午 16:00-17:00 举行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一）会议召开时间：2023 年 09 月 28 日（星期四）下午 16:00-17:00 会议召开时间：2023 年 09 月 28 日(星期四)下午 16:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证 ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately RMB 6.33 billion, a decrease of 12.05% compared to the same period last year[22]. - The net profit attributable to shareholders for the first half of 2023 was approximately RMB 33.4 million, down 96.16% year-on-year[22]. - The basic earnings per share for the first half of 2023 was RMB 0.01, a decrease of 96.88% compared to the previous year[23]. - The gross profit margin dropped to 21% from 32% year-on-year, with gross profit amounting to RMB 1.33 billion, down 41% from RMB 2.27 billion[52]. - The net profit attributable to shareholders was approximately RMB 33.4 million, a significant decline of 97% from RMB 87 million in the previous year[52]. - The company reported a profit before tax of CNY 55,116,368, down from CNY 1,109,746,129 in the previous year, indicating a significant drop in profitability[144]. - The total comprehensive income for the first half of 2023 was a loss of CNY 2,334,015, compared to a total comprehensive income of CNY 450,917,089 in the first half of 2022[148]. Cash Flow and Financial Position - The net cash flow from operating activities increased by 244.96% to approximately RMB 1.18 billion compared to the same period last year[22]. - The company reported a cash balance of approximately RMB 870 million as of June 30, 2023, an increase of about RMB 73 million from December 31, 2022, due to significant improvements in working capital[54]. - The total cash inflow from investment activities was ¥27,192,789, while cash outflow was ¥860,859,518, resulting in a net cash flow from investment activities of (¥833,666,729)[152]. - The total cash and cash equivalents at the end of the period were ¥869,547,965, up from ¥767,427,558 at the end of the previous year[152]. - The company reported a significant decrease in investment income, with a loss of CNY 0 compared to a gain of CNY 455,546,000 in the first half of 2022[146]. Assets and Liabilities - The total assets at the end of the reporting period were approximately RMB 21.69 billion, reflecting a 1.63% increase from the previous year[22]. - Total liabilities reached CNY 6,611,004,746, compared to CNY 6,390,567,553 at the end of 2022, indicating a growth in liabilities[138]. - The company's total equity attributable to shareholders increased to CNY 15,056,324,222 from CNY 14,933,588,455, reflecting a growth of approximately 0.8%[138]. - The company's total assets at the end of the reporting period were 18,372,894,000 RMB, up from 14,027,383,990 RMB, marking a growth of approximately 30.9%[165]. Research and Development - The company operates 8 R&D centers with approximately 300 employees focused on research and innovation, supporting its dual pillar strategy[30]. - Research and development expenses increased by 23.06% to RMB 202.83 million, reflecting accelerated innovation projects[56]. - The R&D expenses for new technologies and products were reported at 45,089,442 RMB, reflecting the company’s commitment to innovation[162]. Market and Product Development - The company has expanded its liquid methionine production capacity by 80,000 tons per year since Q3 2021 to meet growing market demand[32]. - The company has launched two new rumen-protected methionine products, Stramin® and Meistr®, aimed at improving milk quality and cow health while reducing nitrogen emissions[36]. - The company is actively developing new products and solutions to help farmers produce poultry, pigs, and aquaculture more sustainably, reducing antibiotic use and improving animal health[39]. - The company plans to expand its market presence through strategic acquisitions and new product launches in the upcoming quarters[162]. Environmental and Sustainability Initiatives - The company emphasizes safety and sustainability, aiming for a zero-accident workplace and implementing challenging environmental impact reduction goals[30]. - The company is committed to reducing waste emissions and improving raw material utilization in animal production processes[29]. - The company aims to reduce greenhouse gas emissions, energy consumption, and water usage by 20% per kilogram of product compared to 2015 levels, achieving this target ahead of the 2025 deadline[113]. - The company has invested nearly 300 million RMB annually in HSE initiatives over the past three years, with environmental protection investments averaging 50% of total HSE investments[112]. Risks and Challenges - The company faces various risks, including political, regulatory, and economic competition risks, particularly in its global operations[68]. - The company is exposed to raw material supply risks, with reliance on a limited number of suppliers for key inputs like propylene and sulfur, which could affect its financial performance[74]. - The company is at risk of losing competitive advantage if it fails to innovate or if competitors introduce superior products or technologies[75]. - The company faces significant risks from production facility shutdowns and disease outbreaks, which could adversely impact its business and financial performance[80]. Management and Governance - Key management changes include the appointment of Hao Zhigang as CEO effective July 1, 2023, and Frederic Jacquin as COO[96]. - The company held its annual general meeting on May 31, 2023, where all proposed resolutions were approved, including the financial report and profit distribution plan[93]. - The company has not reported any significant litigation or arbitration matters during the reporting period[118].

蓝星安迪苏股份有限公司（以下简称"公司"）已于 2023 年 3 月 31 日、2023 年 4 月 27 日发布公司 2022 年度报告、2023 年一季度财务报表。为便于广大投 资者更全面、更深入地了解中国中化控股有限责任公司（以下简称"中国中化"） 所属上市公司，同时以更为丰富、便捷的形式与投资者进行交流和互动，根据中 国中化统一安排，公司将与中国中化所属的其他 6 家上交所上市公司于 2023 年 5 月 12 日（星期五）下午共同参加集体业绩说明会。 一、 说明会类型 本次会议系中国中化举办的首次集体业绩说明会，旨在加强与投资者沟 召开时间：2023 年 05 月 12 日(星期五)下午 14:00-18:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：现场交流、视频直播和网络文字互动 问题征集：投资者可于 2023 年 05 月 11 日(星期四) 16:00 前登录上证路演中 心 网 站 首 页 点 击 " 提问预征集 " 栏目或通过公司邮箱 InvestorServi ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥3,151,977,858, representing a decrease of 8.83% compared to the same period last year[4]. - The net profit attributable to shareholders was ¥1,487,743, down 99.65% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥22,863,841, a decline of 105.38% compared to the previous year[4]. - The basic and diluted earnings per share were both ¥0.0006, reflecting a decrease of 99.65% year-on-year[4][9]. - The weighted average return on equity decreased by 3.02 percentage points to 0.01%[4][9]. - The total profit for Q1 2023 was CNY 17,155,107, compared to CNY 551,935,746 in the same period last year, indicating a substantial decline[20]. - The company's operating profit for Q1 2023 was CNY 19,131,658, down from CNY 552,132,895 in Q1 2022[20]. - The company’s earnings per share (EPS) for Q1 2023 was CNY 0.00, compared to CNY 0.16 in Q1 2022[21]. Cash Flow and Assets - The net cash flow from operating activities increased by 44.12% to ¥525,623,605, attributed to strict working capital and cash management[4][9]. - The cash flow from operating activities in Q1 2023 was CNY 525,623,605, an increase from CNY 364,716,123 in Q1 2022[24]. - The company's cash and cash equivalents were reported at ¥776,084,627, down from ¥796,360,472, a decrease of 2.4%[14]. - The cash and cash equivalents at the end of Q1 2023 were CNY 776,084,627, down from CNY 1,220,184,242 at the end of Q1 2022[25]. - The company experienced a net cash outflow from investing activities of CNY 523,325,749 in Q1 2023, compared to CNY 482,672,693 in Q1 2022[24]. - Total assets at the end of Q1 2023 were ¥21,519,502,988, an increase of 0.83% from the end of the previous year[5]. - The company's total assets reached ¥21,519,502,988, up from ¥21,343,401,913, indicating a growth of 0.8%[17]. Costs and Expenses - Total operating costs increased to ¥3,139,009,504, up from ¥2,880,492,819 in the same period last year, reflecting a rise of 9.0%[18]. - Research and development expenses rose to ¥99,800,857, compared to ¥69,723,455 in Q1 2022, marking an increase of 43.0%[18]. - The company reported a significant pressure on profitability due to high inventory costs despite sustained sales growth[7][9]. Equity and Liabilities - Shareholders' equity attributable to the parent company was ¥14,996,879,006, up 0.42% from the end of last year[5]. - Total liabilities increased to ¥6,503,309,945, compared to ¥6,390,567,553, representing a rise of 1.8%[16]. - The total equity attributable to shareholders rose to ¥14,996,879,006, compared to ¥14,933,588,455, an increase of 0.4%[17]. Revenue and Income - Total revenue for Q1 2023 was ¥3,151,977,858, a decrease of 8.8% compared to ¥3,457,385,114 in Q1 2022[18]. - The company’s revenue from sales of goods and services in Q1 2023 was CNY 3,515,165,666, compared to CNY 3,407,635,541 in Q1 2022, showing growth[22]. - The company reported a significant increase in other income to CNY 6,551,903 in Q1 2023 from CNY 578,980 in Q1 2022[20]. Non-Recurring Gains - Non-recurring gains included government subsidies of ¥3,601,672 and fair value changes of other non-current financial assets amounting to ¥29,627,600[6].

Financial Performance - The net profit attributable to shareholders for 2022 was RMB 1,246,679,835, representing a significant achievement for the company[6]. - The total distributable profit for the parent company as of December 31, 2022, was RMB 509,781,066[6]. - The proposed cash dividend is RMB 1.51 per 10 shares, totaling RMB 404,967,092 (including tax) to be distributed to all shareholders[6]. - The company's operating revenue for 2022 was CNY 14,529,015,609, representing a 12.90% increase compared to CNY 12,868,681,379 in 2021[25]. - The net profit attributable to shareholders for 2022 was CNY 1,246,679,835, a decrease of 15.29% from CNY 1,471,648,465 in 2021[25]. - The basic earnings per share for 2022 was CNY 0.46, down 16.36% from CNY 0.55 in 2021[26]. - The weighted average return on equity for 2022 was 8.71%, a decrease of 1.83 percentage points from 10.54% in 2021[26]. - The company's revenue for 2022 was RMB 14,529,015,609, an increase of 12.90% compared to 2021[81]. - Operating costs rose to RMB 10,531,745,480, reflecting a 24.27% increase year-on-year[81]. - The company reported a significant increase in financial expenses, up 911.08% to RMB 169,404,162, mainly due to interest increases and foreign exchange fluctuations[81]. Risk Management - The company reported no significant risks that could materially affect its operations during the reporting period[10]. - The company has not experienced any non-operating fund occupation by controlling shareholders or related parties[8]. - The company has not violated any decision-making procedures regarding external guarantees[9]. - The company emphasizes the importance of risk awareness regarding forward-looking statements in the report[7]. - The company has a strong risk resilience due to its significant position in the food value chain, allowing it to implement strict cost control and improve production processes[44]. - The company faces risks related to political, regulatory, and environmental factors that could impact its operations and profitability[151][154]. - Andyso faces significant risks related to raw material and energy supply due to high inflation affecting costs and limited suppliers for key materials like propylene, sulfur, methanol, ammonia, and natural gas[160]. - Customer credit risk remains a concern despite measures like setting credit limits and tracking credit records, which cannot fully eliminate the risk[163]. - The company faces potential tax and tariff risks due to geopolitical tensions and changes in tax laws, which could lead to higher effective tax rates[165]. - Cybersecurity threats, including hacking and phishing, pose risks to the company's information systems, which could lead to significant operational and financial repercussions[172]. Sustainability and Environmental Goals - The company aims to reduce greenhouse gas emissions, energy consumption, and water usage by 20% per kilogram of product by 2025 compared to 2015 levels[40]. - In 2022, the company set a new target to reduce absolute greenhouse gas emissions by 21% by 2025 compared to 2020 levels, aligning with science-based targets[41]. - The company is committed to sustainability, aiming for a balance between economic development and resource protection, and aligns its goals with international standards such as the Paris Agreement[41]. - The company is investing in environmental projects, including new electrostatic filters and wastewater treatment facilities, to reduce production's environmental impact and improve cost competitiveness[69]. - The company is committed to reducing greenhouse gas emissions and energy consumption as part of its sustainability efforts[154]. Research and Development - The company has eight R&D centers with approximately 200 employees dedicated to research and innovation, supporting its dual pillar strategy[39]. - The company’s R&D innovation center in China began trial operations in early 2022, with a 20% increase in the R&D team, resulting in 4 out of 7 new patent applications being approved[45]. - Total R&D investment amounted to CNY 470,034,898, representing 3.24% of operating revenue[92]. - The company reported a 20% increase in full-time R&D personnel in 2022, with 4 out of 7 new patent applications approved[143]. - The company has established a research center in Singapore and is collaborating with universities and research institutions to enhance R&D capabilities[94]. Market Position and Strategy - The company is a leader in the global animal nutrition feed additive market, providing comprehensive solutions through strategic partnerships, products, services, and research[36]. - The company serves over 4,200 customers in more than 110 countries, focusing on improving production efficiency, animal performance, and minimizing environmental impact[36]. - The company is the global leader in liquid methionine and the second-largest producer of methionine overall, with a unique competitive advantage in feed-grade vitamins[38]. - The company has established a "dual pillar" strategy to strengthen its leading position in the methionine industry while accelerating the development of specialty products[37]. - The company aims to maintain its leading position in the methionine market while accelerating the development of specialty products through continuous innovation[68]. - The company is actively seeking external acquisition opportunities to drive revenue growth[145]. - The company has established strategic alliances and external acquisitions to enhance its core business and diversify its high-growth product portfolio[70]. Operational Efficiency - The company has implemented optimization plans in response to economic challenges, including rising raw material prices and geopolitical crises affecting energy costs[52]. - The company has maintained a stable business operation level despite global macroeconomic volatility, including geopolitical tensions and rising raw material costs[44]. - The company is committed to reducing production costs by integrating upstream and downstream processes for methionine production, ensuring the stability and reliability of high-risk intermediates[76]. - The company aims to reduce operational costs by 8% through efficiency improvements in production[195]. Governance and Management - The company’s board of directors includes members with extensive experience in chemical engineering and management, enhancing its strategic direction[192]. - The company has a diverse board with members from various backgrounds, which supports its global operations and strategic initiatives[192]. - The company held two shareholder meetings in the year, with all proposals approved and no rejected resolutions[188]. - The total remuneration for the board members and senior management during the reporting period amounted to 2,712,000 RMB[192]. - The company has renewed the responsibility insurance for directors, supervisors, and senior management personnel[188]. - The leadership team includes individuals with academic and professional expertise, contributing to informed decision-making processes[200].